151377-80-9

Usage

Uses

Used in the Food Industry:
.alpha.-L-Tagatofuranose, 1,2:3,4-bis-O-(1-methylethylidene)is used as a potential low-calorie sweetener for the food industry due to its altered chemical properties compared to the original tagatose. It is being researched for its effects on blood sugar levels, making it a promising candidate for products that require sugar substitutes.
Used in the Pharmaceutical Industry:

Upstream product

• 151377-79-6 1,2:4,6-Di-O-isopropylidene-α-L-tagatofuranose 
• 18604-19-8 11,2:4,6-di-O-isopropylidene-α-L-sorbofuranose 
• 41847-60-3 L-tagatose 
• 67-64-1 acetone 

Downstream Products

• 151252-21-0 (3aS,4R,7S,7aR)-4-(tert-Butyl-dimethyl-silanyloxymethyl)-2,2-dimethyl-hexahydro-[1,3]dioxolo[4,5-c]pyridin-7-ol 
• 151252-18-5 (3aR,6S,6aR)-6-Azidomethyl-4-hydroxymethyl-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-ol 
• 151252-15-2 6-Azido-6-deoxy-1,2:3,4-di-O-isopropylidene-α-L-tagatose 

Relevant academic research and scientific papers

Looking-glass synergistic pharmacological chaperones: DGJ and L-DGJ from the enantiomers of tagatose

The enantiomers of tagatose are converted to l-DGJ [a noncompetitive inhibitor of human lysosome α-galactosidase A (α-Gal A), K i 38.5 μM] and DGJ [a competitive inhibitor of α-Gal A, Ki 15.1 nM] in 66% yield. l-DGJ and DGJ provide the first examples of pharmacological chaperones that (a) are enantiomeric iminosugars and (b) have synergistic activity with implications for the treatment of lysosomal storage disorders and other protein deficiencies.

Synthesis of 1,5-dideoxy-1,5-imino-D-galactitol fromL-sorbose

A facile new synthesis of 1-deoxygalactonojirimycin (1) [1,5-dideoxy-1,5-imino-D-galactitol] is described. The L-sorbose derivative (15) is epimerised at C-3 and converted, via the L-tagatofuranose (18) into the deoxyazide (20). Reduction of azide (20) and deprotection affords 1-deoxygalactonojirimycin (1).